Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Sep 20, 2019 11:47am

177 Views

Post# 30148068

RE:RE:RE:RE:RE:RE:RE:RE:RE:R&D Day 10/23 in NYC

Thank you. Very interesting. Wonder if she knows about Egri fta and if TH knows about her. In fact they must know her but the question is do they ever had any conversations with her about Egri fta and NASH.

qwerty22 wrote: I like this doc. She has published some interesting papers recently and a few of her conference presentation are online. Here's a nice audio with slides from this years CROI as a general overview of hiv nash, and she's based at Mcgill in Montreal.

https://www.croiwebcasts.org/p/2019croi/2008

Wino115 wrote: Has Mgmt said anything about including some heavyweight Key Industry/Opinion Leaders at this R&D event to lend some serious credibility to the strategy or rationale? I would seriously shake the tree and offer full-paid expenses for Grinspoon (or someone in that lab team), the NIH Doctor who is co-author (& has a horses mouth if you know what I mean), one of their FDA consultants to review the Phase 3 proposal, other key industry people on both HIV NASH and Oncology.

If they really want to go over the top, they could actually bring along Dopey and his Incontinence Products.